Nobuki Imano1,2, Yuji Murakami3, Takeo Nakashima4, Yuki Takeuchi3, Ippei Takahashi3, Yoshiko Doi3, Ikuno Nishibuchi3, Tomoki Kimura3, Koichi Wadasaki5, Tsutomu Ueda6, Katsuhiro Hirakawa6, Yasushi Nagata3. 1. Department of Radiation Oncology, Hiroshima University Graduate School of Biomedical Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. imano0118@gmail.com. 2. Department of Radiation Oncology, Hiroshima Prefectural Hospital, Hiroshima, Japan. imano0118@gmail.com. 3. Department of Radiation Oncology, Hiroshima University Graduate School of Biomedical Sciences, 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8551, Japan. 4. Department of Clinical Support, Section of Radiation Therapy, Hiroshima University Hospital, Hiroshima, Japan. 5. Department of Radiation Oncology, Hiroshima Prefectural Hospital, Hiroshima, Japan. 6. Department of Otolaryngology, Head and Neck Surgery, Hiroshima University Graduate School of Biomedical Sciences, Hiroshima, Japan.
Abstract
PURPOSE: The purpose of this study was to analyze the clinical results of concurrent chemoradiotherapy (CCRT) with volumetric modulated arc therapy (VMAT) for nasopharyngeal carcinoma (NPC) patients. MATERIALS AND METHODS: Patients with stage II-IVB NPC who received CCRT with VMAT between 2010 and 2014 were included in this study. The planned dose was 70 Gy in 35 fractions. RESULTS: Twenty patients aged between 28 and 85 years (median 60 years) were assessed. With a median follow-up time of 47 months, the 3-year overall survival and progression-free survival rates were 85 and 65%, respectively. The 3-year local, regional and distant control rates were 78, 88 and 79%, respectively. At 0, 3, 6 and 12 months from CCRT, 19, 6, 3, and 1 patients had grade 2 dry mouth, respectively. No cases of grade 3 or worse dry mouth were observed. The severity of dry mouth was downgraded from grade 2 to grade 0 or 1 significantly earlier in younger patients (<70 years, p = 0.02) or patients in whom the mean dose to one parotid gland was lower (<26 Gy, p = 0.04). CONCLUSIONS: Our clinical results regarding CCRT with VMAT for NPC patients showed favorable survival rates while maintaining organ function.
PURPOSE: The purpose of this study was to analyze the clinical results of concurrent chemoradiotherapy (CCRT) with volumetric modulated arc therapy (VMAT) for nasopharyngeal carcinoma (NPC) patients. MATERIALS AND METHODS:Patients with stage II-IVB NPC who received CCRT with VMAT between 2010 and 2014 were included in this study. The planned dose was 70 Gy in 35 fractions. RESULTS: Twenty patients aged between 28 and 85 years (median 60 years) were assessed. With a median follow-up time of 47 months, the 3-year overall survival and progression-free survival rates were 85 and 65%, respectively. The 3-year local, regional and distant control rates were 78, 88 and 79%, respectively. At 0, 3, 6 and 12 months from CCRT, 19, 6, 3, and 1 patients had grade 2 dry mouth, respectively. No cases of grade 3 or worse dry mouth were observed. The severity of dry mouth was downgraded from grade 2 to grade 0 or 1 significantly earlier in younger patients (<70 years, p = 0.02) or patients in whom the mean dose to one parotid gland was lower (<26 Gy, p = 0.04). CONCLUSIONS: Our clinical results regarding CCRT with VMAT for NPCpatients showed favorable survival rates while maintaining organ function.
Authors: Vincent Grégoire; Peter Levendag; Kian K Ang; Jacques Bernier; Marijel Braaksma; Volker Budach; Cliff Chao; Emmanuel Coche; Jay S Cooper; Guy Cosnard; Avraham Eisbruch; Samy El-Sayed; Bahman Emami; Cai Grau; Marc Hamoir; Nancy Lee; Philippe Maingon; Karin Muller; Hervé Reychler Journal: Radiother Oncol Date: 2003-12 Impact factor: 6.280
Authors: Patricia Doornaert; Wilko F A R Verbakel; Michael Bieker; Ben J Slotman; Suresh Senan Journal: Int J Radiat Oncol Biol Phys Date: 2010-04-24 Impact factor: 7.038
Authors: Sara Broggi; Lucia Perna; Francesco Bonsignore; Giuseppe Rinaldin; Claudio Fiorino; Anna Chiara; Cristina Frigerio; Ivana Butti; Giulia Sangalli; Italo Dell'Oca; Nadia Di Muzio; Giovanni Mauro Cattaneo; Fausto Declich Journal: Phys Med Date: 2014-08-10 Impact factor: 2.685
Authors: Suzanne L Wolden; William C Chen; David G Pfister; Dennis H Kraus; Sean L Berry; Michael J Zelefsky Journal: Int J Radiat Oncol Biol Phys Date: 2005-06-02 Impact factor: 7.038
Authors: Anne W M Lee; W H Lau; Stewart Y Tung; Daniel T T Chua; Rick Chappell; L Xu; Lillian Siu; W M Sze; T W Leung; Jonathan S T Sham; Roger K C Ngan; Stephen C K Law; T K Yau; Joseph S K Au; Brian O'Sullivan; Ellie S Y Pang; S K O; Gordon K H Au; Joseph T Lau Journal: J Clin Oncol Date: 2005-10-01 Impact factor: 44.544
Authors: Michael K M Kam; Peter M L Teo; Ricky M C Chau; K Y Cheung; Peter H K Choi; W H Kwan; S F Leung; Benny Zee; Anthony T C Chan Journal: Int J Radiat Oncol Biol Phys Date: 2004-12-01 Impact factor: 7.038
Authors: Wilko F A R Verbakel; Johan P Cuijpers; Daan Hoffmans; Michael Bieker; Ben J Slotman; Suresh Senan Journal: Int J Radiat Oncol Biol Phys Date: 2009-05-01 Impact factor: 7.038
Authors: Xiaofang Dai; Yingchao Zhao; Zhiwen Liang; Meera Dassarath; Lu Wang; Lihui Jin; Lili Chen; James Dong; Robert A Price; C-M Ma Journal: Phys Med Date: 2014-10-03 Impact factor: 2.685